Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RAD51C del |
| Therapy | unspecified PARP inhibitor |
| Indication/Tumor Type | ovarian cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RAD51C del | ovarian cancer | predicted - sensitive | unspecified PARP inhibitor | Case Reports/Case Series | Actionable | In a clinical study, PARP inhibitor monotherapy (niraparib (n=1), olaparib (n=5) or rucaparib (n=2)), resulted in a median progression-free survival (PFS) of 25.4 mo and an overall survival (OS) of 51.8 mo in ovarian cancer patients with homozygous deletion of homologous recombination repair (HRR) genes (n=8) including RAD51C (n=1), compared to a median PFS of 4.9 mo and OS of 18.5 mo in patients without HRR gene alterations (n=198) (PMID: 42133897). | 42133897 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (42133897) | Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer. | Full reference... |